Impact of weight trajectory after bariatric surgery on co-morbidity evolution and burden

Abstract

Background: Bariatric surgery, such as Roux-en-Y gastric bypass [RYGB] has been shown to be an effective intervention for weight management in select patients. After surgery, different patients respond differently even to the same surgery and have differing weight-change trajectories. The present analysis explores how improving a patient's post-surgical weight change could impact co-morbidity prevalence, treatment and associated costs in the Canadian setting. Methods: Published data were used to derive statistical models to predict weight loss and co-morbidity evolution after RYGB. Burden in the form of patient-years of co-morbidity treatment and associated costs was estimated for a 100-patient cohort on one of 6 weight trajectories, and for real-world simulations of mixed patient cohorts where patients experience multiple weight loss outcomes over a 10-year time horizon after RYGB surgery. Costs (2018 Canadian dollars) were considered from the Canadian public payer perspective for diabetes, hypertension and dyslipidaemia. Robustness of results was assessed using probabilistic sensitivity analyses using the R language. Results: Models fitted to patient data for total weight loss and co-morbidity evolution (resolution and new onset) demonstrated good fitting. Improvement of 100 patients from the worst to the best weight loss trajectory was associated with a 50% reduction in 10-year co-morbidity treatment costs, decreasing to a 27% reduction for an intermediate improvement. Results applied to mixed trajectory cohorts revealed that broad improvements by one trajectory group for all patients were associated with 602, 1710 and 966 patient-years of treatment of type 2 diabetes, hypertension and dyslipidaemia respectively in Ontario, the province of highest RYGB volume, corresponding to a cost difference of $3.9 million. Conclusions: Post-surgical weight trajectory, even for patients receiving the same surgery, can have a considerable impact on subsequent co-morbidity burden. Given the potential for alleviated burden associated with improving patient trajectory after RYGB, health care systems may wish to consider investments based on local needs and available resources to ensure that more patients achieve a good long-term weight trajectory.

Effects of bariatric surgery on cardiovascular‐related acute care use in patients with hypertrophic cardiomyopathy

“…Thus, there may be unmeasured confounders that are not included in the model. Third, our follow‐up period was 12 months because most significant weight changes following bariatric surgery occur within 12 months and weight stabilizes in a majority of patients thereafter 54 . However, longer follow‐up is ultimately warranted to establish long‐term effects of bariatric surgery on cardiovascular‐related acute care use in patients with HCM.…”

Earlier Provision of Gastric Bypass Surgery in Canada Enhances Surgical Benefit and Leads to Cost and Comorbidity Reduction

“…Considerable differences have been reported in weight loss trajectory after bariatric surgeries (27)(28)(29). One previous analysis has characterized outcomes in comorbidity resolution according to trajectory (27) and another considered the cost implications of comorbidity evolution for RYGB in the Canadian setting (14). Outcomes across Canadian studies of RYGB were assessed (Supplementary Materials, section 2, Supplementary Table 3) to determine trajectory groups from the study of Courcoulas et al (27) that most closely resemble Canadian outcomes.…”

“…A recent study of patients in the Ontario Bariatric Network, a centralized management system for all bariatric surgery referrals in the province, noted the potential negative cost impact of prolonged presurgical patient workup and its contribution to patient attrition (11). Other modeling studies based on published data from Canada have sought to quantify the cost burden associated with the current standard of care in comparison to an improved complete SG bariatric surgery care pathway in Canada (13), and focused on the post-surgical period for RYGB (14). These studies identified potential savings in costs and reduced patient comorbidity with realistic improvements to the presurgical wait time and post-surgical weight loss trajectories.…”

Amoxicillin dosing and pharmacokinetics in obesity for the treatment of bacterial respiratory infection secondary to COVID-19: a systematic review

“…Obesity is likely to cause several morbidities including hypertension, diabetes, cardiovascular diseases, and pulmonary arterial hypertension among other (De Lorenzo et al, 2020;Tchang et al, 2021;Caci et al, 2020). In order to mitigate complications of obesity-related comorbidities, patients may undergo bariatric surgery, although with limited success as most of them remain obese or regain the weight lost after 2 or more years post-surgery (Davis & Saunders, 2020). In addition, other issues related to the bariatric procedures may also arise, given that the gastrointestinal physiology relevant for oral drug absorption (stomach, duodenum, and part of jejunum) is altered, especially after Roux-en-Y Gastric Bypass (RYGB).…”